COMMUNIQUÉS West-GlobeNewswire

Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting
08/05/2019
NEW YORK and CLEVELAND, May 08, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that long-term follow up data from a completed Phase [...]
Matinas BioPharma to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 14, 2019
08/05/2019
BEDMINSTER, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live [...]
Better Choice Company to Participate in the Canaccord Genuity Conference on May 14
08/05/2019
NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (OTCQB: BTTR) (the “Company”) today announced that Damian Dalla-Longa, Co-CEO of Better Choice, will present at the Canaccord Genuity Conference to [...]
Allakos Reports First Quarter 2019 Financial Results
08/05/2019
REDWOOD CITY, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial [...]
Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
08/05/2019
– First Quarter Revenues of $22.2 Million; Andexxa ® Product Revenues Grow 45% to $20.3 Million – – European Commission Approval of Ondexxya ® ; Staged Commercial Launch Planned in Second Half of 2019 – – Conference [...]
Proteon Therapeutics Announces First Quarter 2019 Financial Results
08/05/2019
WALTHAM, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular [...]
Neon Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference
08/05/2019
CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief [...]
Cybrexa Therapeutics to Present at the 2019 BIO International Convention
08/05/2019
NEW HAVEN, Conn., May 08, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Per [...]
Alder BioPharmaceuticals® Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine Prevention
08/05/2019
- Data presented at the 2019 American Academy of Neurology (AAN) meeting demonstrate nearly 60% of patients reported very much or much improvement in most bothersome symptoms and in overall migraine status following two [...]
Altimmune to Announce First Quarter 2019 Financial Results on May 15
08/05/2019
GAITHERSBURG, Md., May 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March [...]
Allena Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
08/05/2019
-- Entered into Agreement with Duke Clinical Research Institute (DCRI) to Support Phase 3 URIROX-2™ Trial and Promote Enteric Hyperoxaluria Disease Awareness – -- All Clinical Programs Progressing on Track; Expect to [...]
BioCardia Receives FDA Clearance for AVANCE Steerable Introducer for Transseptal Access to Heart
08/05/2019
SAN CARLOS, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced U.S. Food and Drug [...]
Kura Oncology to Present at Bank of America Merrill Lynch Health Care Conference
08/05/2019
SAN DIEGO, May 08, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson [...]
Progressive Care to Host Conference Call on the 2019 Quarterly Filing and Business Update on May 15th, 2019
08/05/2019
MIAMI, May 08, 2019 (GLOBE NEWSWIRE) -- Progressive Care Inc. ( OTCQB: RXMD ), a personalized healthcare services and technology company, is pleased to announce that the Company has scheduled an investor conference call [...]
Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research
08/05/2019
SAN DIEGO, May 08, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel progesterone [...]
CymaBay Therapeutics Announces Multiple Presentations at DDW 2019
08/05/2019
NEWARK, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that multiple abstracts related to its seladelpar clinical development program for the treatment of primary [...]
PSIQ to Acquire 80% of Ecoland Including Multiple Cannabis Licenses, Operations and Real Estate for Approximately $18,300,000
08/05/2019
SUNRISE, Fla., May 08, 2019 (GLOBE NEWSWIRE) -- Profile Solutions, Inc. (OTC Pink: PSIQ) is pleased to announce the proposed acquisition of 80% of the Capital Stock and Assets of Ecoland K.K.L. LTD, an Israel LTD. and [...]
C-RAD AB – Interim report January-March 2019
08/05/2019
C-RAD AB – Interim report January-March 2019 REVENUE INCREASE OF 40 PERCENT JANUARY - MARCH 2019 Revenues: 47.3 (33.8) MSEK Order intake: 47.8 (50.6) MSEK EBITDA: 3.6 (-3.6) MSEK Operating profit: 1.2 (-4.7) MSEK Net [...]
Oxurion NV : Oxurion NV Business Update - Q1 2019
08/05/2019
Oxurion NV Business Update - Q1 2019 Significant Progress with Novel Clinical Diabetic Eye Disease Portfolio Enrollment of THR-317 Phase 2 Combination Study & THR-149 Phase 1 Study Completed Ahead of Schedule First [...]

Pages